Group 1 - Jiejia Weichuang expects a net profit of 1.7 billion to 1.96 billion yuan for the first half of 2025, representing a year-on-year increase of 38.65% to 59.85% [1] - Micron Biotech's CS231295 clinical trial application has been approved by the FDA for treating advanced solid tumors [1] - Sinopec anticipates a net profit of 20.1 billion to 21.6 billion yuan for the first half of 2025, a decrease of 39.5% to 43.7% year-on-year [2] Group 2 - High Energy Environment has obtained a loan commitment letter from a financial institution for share repurchase [2] - Electric Power Investment Energy received a warning letter from the Inner Mongolia Securities Regulatory Bureau for inadequate disclosure in its semi-annual report [3] - Zhejiang University Net New won a bid for an intelligent engineering project worth 94.2712 million yuan [5] Group 3 - Daodaoquan reported a net profit of 181 million yuan for the first half of 2025, a year-on-year increase of 563.15% [8] - New Light Optoelectronics expects a net loss of 19 million to 23 million yuan for the first half of 2025 [9] - Aihua Pharmaceutical's two probiotic powder registration applications have been accepted [10] Group 4 - Xinhui Electric's subsidiary signed a product sales framework contract for commercial and household robots [11] - Baida Precision Engineering's subsidiary obtained 134,500 square meters of industrial land use rights [12] - Haiyang Technology's chief engineer resigned for personal reasons [13] Group 5 - Tianhe Magnetic Materials received a project filing notice for a 12,000-ton magnetic material deep processing project [22] - Wanlima is the pre-selected unit for a procurement project worth 43.835 million yuan from China Southern Airlines [24] - Yipin Hong's subsidiaries obtained two drug registration certificates [25] Group 6 - Zhejiang Jiaoke's subsidiary signed new construction projects worth 4.783 billion yuan in the second quarter [27] - Shenglan Co. received approval for issuing convertible bonds [29] - Jimi Technology expects a net profit of 88.6622 million yuan for the first half of 2025, a year-on-year increase of 2062.33% [31] Group 7 - Dingtong Technology reported a net profit of 115 million yuan for the first half of 2025, a year-on-year increase of 134.06% [32] - Huaheng Biological is planning to list on the Hong Kong Stock Exchange [34] - Yuntian Lihui submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [36] Group 8 - Nanchip Technology expects a net profit of 108.8 million to 133.1 million yuan for the first half of 2025, a decrease of 35.09% to 47.03% year-on-year [43] - Anglikang's Mesobam injection has received a drug registration certificate [44] - Jida Zhengyuan's shareholder plans to reduce their stake by up to 0.998% [45]

Core Viewpoint - Microchip Biotech (688321.SH) announced that its wholly-owned subsidiary, Microchip Biotech (USA) Co., received a notification from the FDA on July 31, allowing the company to initiate a Phase I clinical trial for its self-developed CS231295 to treat advanced solid tumors [1] Group 1 - CS231295 is a selective AuroraB inhibitor that precisely targets tumor-specific overexpression of AuroraB kinase, inducing synthetic lethality and directly addressing RB1 gene vulnerabilities [1] - The compound demonstrates significant therapeutic advantages for primary or metastatic brain tumors due to its good blood-brain barrier penetration capability [1] - CS231295 also possesses broad-spectrum anti-tumor activity that improves the tumor microenvironment, potentially offering new solutions for various tumor types with similar genetic defects and addressing the global challenge of tumor brain metastasis [1]

7月31日，微芯生物大宗交易成交15万股，成交额460.5万元，占当日总成交额的0.51%，成交价30.7元，较市场收盘价37.25元折价17.58%。 | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | | 2025-07-31 | 微芯生物 | 688321 | 30.7 460.5 | 兴业证券股份有限 公司福州新权路香 | 国投证券股份有限 公司深圳宝安海秀 | | | | | | | 『六三十九十五名 | REST # # # | | ...

Core Viewpoint - Microchip Biotech (688321) announced that its wholly-owned subsidiary, Microchip Biotech (USA) LLC, received notification from the FDA on July 31, allowing the company to initiate a Phase I clinical trial for its self-developed CS231295 targeting advanced solid tumors [1] Group 1 - The FDA has granted permission for the Phase I clinical trial of CS231295 [1] - The trial is focused on treating advanced solid tumors [1] - The notification was received on July 31 [1]

| | | 转债代码：118012 转债简称：微芯转债 深圳微芯生物科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 深圳微芯生物科技股份有限公司（以下简称"公司"）股票交易价格自 2025 年 7 月 11 日至 2025 年 7 月 31 日期间，已满足在连续三十个交易日中至少 十五个交易日的收盘价格不低于"微芯转债"当期转股价格的 130%（即 32.838 元/股），已触发《深圳微芯生物科技股份有限公司向不特定对象发行可转换公 司债券募集说明书》中规定的有条件赎回条款。 公司于 2025 年 7 月 31 日召开第三届董事会第十二次会议，审议通过了 《关于不提前赎回"微芯转债"议案》，决定本次不行使"微芯转债"的提前赎 回权利，不提前赎回"微芯转债"。 在未来三个月内（即 2025 年 8 月 1 日起至 2025 年 10 月 31 日），如果再 次触发"微芯转债"有条件赎回条款，公司亦不提出有条件赎回方案。公司以 2025 年 11 月 3 日（11 月 1 日-2 日为非交易日 ...

Core Viewpoint - Microchip Biotech (688321.SH) announced that its wholly-owned subsidiary, Microchip Biotech (USA) Co., received a notification from the FDA on July 31, allowing the company to initiate a Phase I clinical trial for its self-developed CS231295 to treat advanced solid tumors [1] Group 1: Clinical Trial Approval - The FDA has granted permission for the Phase I clinical trial of CS231295, which targets advanced solid tumors [1] - The trial represents a significant step in the development of innovative cancer therapies [1] Group 2: Mechanism of Action - CS231295 is a selective AuroraB inhibitor that precisely targets tumor-specific overexpression of AuroraB kinase, inducing synthetic lethality by addressing RB1 gene vulnerabilities [1] - The compound demonstrates excellent blood-brain barrier penetration, providing a therapeutic advantage for primary or metastatic brain tumors [1] Group 3: Broader Implications - CS231295 also possesses broad-spectrum anti-tumor activity that can improve the tumor microenvironment [1] - The drug has the potential to offer new solutions for various tumor types with similar genetic defects and address the global challenge of tumor brain metastasis [1]

国投证券股份有限公司 关于深圳微芯生物科技股份有限公司 不提前赎回"微芯转债"的核查意见 国投证券股份有限公司（以下简称"国投证券"、"保荐机构"）作为深圳 微芯生物科技股份有限公司（以下简称"微芯生物"或"公司"）向不特定对象 发行可转换公司债券的持续督导保荐机构，根据《证券发行上市保荐业务管理办 法》《上海证券交易所科创板股票上市规则》《可转换公司债券管理办法》和《上 海证券交易所上市公司自律监管指引第 12 号——可转换公司债券》等有关规 定，对公司不提前赎回"微芯转债"的事项进行了核查，核查情况及核查意见如 下： 一、可转债发行上市概况 经中国证券监督管理委员会"证监许可[2022]1234 号"文同意注册，公司于 2022 年 7 月 5 日向不特定对象发行可转换公司债券 500.00 万张，每张面值为人 民币 100 元，发行总额为人民币 50,000.00 万元（人民币伍亿元整），发行的可 转换公司债券的期限为自发行之日起六年，即自 2022 年 7 月 5 日至 2028 年 7 月 4 日。 经上海证券交易所自律监管决定书〔2022〕195 号文同意，公司发行的 50,000.00 万元可转 ...

证券代码：688321 证券简称：微芯生物 公告编号：2025-046 深圳微芯生物科技股份有限公司 关于 CS231295 临床试验申请获得 FDA 批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 申请人：微芯生物科技（美国）有限公司 结论：CS231295 片临床试验申请获得美国 FDA 批准，同意本品按照提交的 方案开展临床试验。 2、药品的其他情况 CS231295 作为透脑 Aurora B 选择性抑制剂，一方面通过精准抑制肿瘤特异 性过表达的 Aurora B 激酶，诱导合成致死效应，直击 RB1 缺失等难治性肿瘤的 重要内容提示： 深圳微芯生物科技股份有限公司（以下简称"公司"）的全资子公司微芯生 物科技（美国）有限公司于 7 月 31 日收到美国食品药品监督管理局（以下简称 "FDA"）签发的关于允许公司自主研发的 CS231295 开展治疗晚期实体瘤的 I 期 临床试验的通知，现将相关情况公告如下： 一、药品基本情况 1、产品名称：CS231295 片 申请编号：IND 176942 适应症： ...

微芯生物7月30日大宗交易平台出现一笔成交，成交量26.06万股，成交金额800.04万元，大宗交易成交 价为30.70元，相对今日收盘价折价17.36%。该笔交易的买方营业部为机构专用，卖方营业部为国投证 券股份有限公司深圳宝安海秀路证券营业部。 进一步统计，近3个月内该股累计发生35笔大宗交易，合计成交金额为1.88亿元。 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折溢 | 买方营 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 价（%） | 业部 | | | 26.06 | 800.04 | 30.70 | -17.36 | 机构专 | 国投证券股份有限公司深圳宝安海 | | | | | | 用 | 秀路证券营业部 | 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （文章来源：证券时报网） 证券时报·数据宝统计显示，微芯生物今日收盘价为37.15元，下跌3.18%，日换手率为5.23%，成交额为 8.00亿元，全天主力资金净流出4382.72万元，近5日该股累计上涨6.05%，近5日 ...

Core Insights - Microchip Biotech conducted 16 block trades on July 29, totaling 1,899,400 shares and a transaction value of 58.12 million yuan, with an average transaction price of 30.60 yuan, representing a discount of 20.25% compared to the closing price of the day [2][3] - Over the past three months, the stock has seen a total of 34 block trades, amounting to 180 million yuan [2] - The closing price of Microchip Biotech on the same day was 38.37 yuan, reflecting a 12.85% increase, with a turnover rate of 9.85% and a total trading volume of 1.49 billion yuan [2] - The net inflow of main funds for the day was 101 million yuan, while the stock has experienced a cumulative increase of 5.21% over the past five days, with a total net outflow of 188 million yuan during the same period [2] - The latest margin financing balance for the stock is 514 million yuan, showing a decrease of 18.50 million yuan over the past five days, a decline of 3.47% [2] Block Trade Details - The largest single block trade was for 260,000 shares, valued at 7.96 million yuan, executed at the price of 30.60 yuan [2] - Other notable trades included 250,000 shares for 7.65 million yuan and 245,000 shares for 7.50 million yuan, all at the same price of 30.60 yuan [2][3] - The majority of the block trades were executed by institutional specialized seats, with a total net purchase amounting to 19.89 million yuan [2]